https://ojs.wpro.who.int/ 1WPSAR Vol 12, No 2, 2021  | doi: 10.5365/wpsar.2020.11.2.012

Surveillance System Implementation / Evaluation

P
acific island countries and territories (PICTs) are 
marked by expansive geography, relatively small 
populations and diverse cultures. They are also 

vulnerable to emerging infectious diseases, including 
epidemics and pandemics, and to natural disasters, 
including cyclones, earthquakes and tsunamis. For these 
reasons, the World Health Organization’s Asia Pacific 
Strategy for Emerging Diseases and Public Health 
Emergencies (APSED III) guides Member States to adopt 
an all-hazards approach,  encompassing both disease 
outbreaks and natural disasters, to strengthen their 
capacity to detect, prepare for and respond to outbreaks 
of infectious diseases and public health emergencies.1

On 30 January 2020, the WHO Director-General 
declared that the outbreak of novel coronavirus disease 
2019 (COVID-19) constituted a public health emergency 

of international concern. As of 30 April 2020, six PICTs 
had confirmed cases of COVID-19.2 In Vanuatu, a coun-
try of approximately 290 000 people and composed of 
83 islands, the response to COVID-19 is guided by the 
VanGov Plan (COVID-19 Health Sector Preparedness and 
Response Plan) developed in January 2020 and revised 
as the situation evolves.3 Priority actions are categorized 
according to three scenarios: 1 (no cases), 2 (one or 
more cases or clusters) and 3 (community transmission). 
A strategic objective of the plan is to ensure that the 
surveillance system is active and functional. Since Janu-
ary 2020, the Government of Vanuatu has implemented 
several measures to prevent the importation of COVID-19 
and contain and mitigate community transmission, in-
cluding suspending the use of international ports of entry 
into Vanuatu on 23 March 2020 and declaring a state of 
emergency on 26 March 2020.

a Department of Public Health, Vanuatu Ministry of Health, Port Vila, Vanuatu.
b Vanuatu Health Program, Port Vila, Vanuatu.
c Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.
d Burnet Institute, Melbourne, Victoria, Australia.
e Vila Central Hospital, Port Vila, Vanuatu.
f Country Liaison Office, World Health Organization, Port Vila, Vanuatu.
g Private physician, Port Vila, Vanuatu.
h Members of the Vanuatu Ministry of Health’s National Health Emergency Operations Centre are provided in the Acknowledgements.
* These authors contributed equally.
Published: 5 April 2021
doi: 10.5365/wpsar.2020.11.2.012

The Pacific island nation of Vanuatu is vulnerable to emerging infectious diseases, including epidemics and pandemics; 
chronic food and water insecurity; and natural hazards, including cyclones, earthquakes, tsunamis, landslides and flooding. 
In March 2020, the World Health Organization characterized the outbreak of novel coronavirus disease 2019 (COVID-19) 
as a global pandemic. By the end of April 2020, Vanuatu had reported no confirmed cases of COVID-19. Data from 
several sources are collected in Vanuatu’s COVID-19 surveillance system to provide an overview of the situation, including 
data from case investigations and management, syndromic surveillance for influenza-like illness, hospital surveillance 
and laboratory surveillance. Review of data collected from January to the end of April 2020 suggests that there was 
no sustained increase in influenza-like illness in the community and no confirmed cases were identified. Lessons learnt 
from the early implementation of surveillance activities, the changing landscape of laboratory testing and pharmaceutical 
interventions, as well as the global experience, particularly in other Pacific island countries, will inform the refinement of 
COVID-19 surveillance activities in Vanuatu.

Challenges to implementation and 
strengthening of initial COVID-19 
surveillance in Vanuatu: January–April 2020
Wendy Williams,a,* Caroline van Gemert,b,c,d,* Joanne Mariasua,a Edna Iavro,a Debbie Fred,a,b Johnny Nausien,a 
Obed Manwo,a Vincent Atua,a,e George Junior Pakoa,a,e Annie Taissets,a Tessa B Knox,f Michael Buttsworth,f  
Geoff Clark,b Matthew Cornish,g Posikai Samuel Tapo,a Len Tarivonda,a and Philippe Guyant,f on behalf of the 
Vanuatu Ministry of Health’s National Health Emergency Operations Centreh

Correspondence to Caroline van Gemert (email: caroline.vangemert@unimelb.edu.au or caroline.vangemert@vhp.com.vu).



WPSAR Vol 12, No 2, 2021  | doi: 10.5365/wpsar.2020.11.2.012 https://ojs.wpro.who.int/2

Williams et alCOVID-19 surveillance in Vanuatu, January–April 2020

Enhancement of systems for COVID-19 surveil-
lance

A sentinel surveillance system for private clinics 
in Port Vila was established in March 2020 among 
general practitioners. The objective was to rapidly 
identify imported cases and monitor community-level 
transmission of COVID-19 among expatriates, who pre-
dominantly use private clinics. Clinics were requested 
to submit daily reports via a web form of the number 
of consultations and the number of people presenting 
with ILI (Table 2).

Active hospital-based surveillance activities were 
established in April 2020 to monitor and rapidly identify 
any cases of severe acute respiratory infection (SARI) 
or pneumonia-related presentations to emergency de-
partments, and hospitalizations and deaths. Data were 
collected daily from the main referral hospital in Port 
Vila and five provincial hospitals (Table 2). In addition, 
data on the number of tablets of paracetamol dispensed 
through the emergency department were collected 
weekly. A surveillance officer contacted all hospitals 
daily to verbally collect information on new admissions 
for SARI or pneumonia, and weekly for paracetamol 
dispensing.

Case investigation and management

Protocols were developed to investigate all suspected 
cases: a public health officer interviews all suspected 
cases to determine whether the person meets the case 
definition and the possible source of transmission, to 
identify close contacts and to implement steps to mini-
mize ongoing transmission.

The initial protocol implemented in January 2020 
was for suspected cases to be immediately isolated 
at home to prevent onward transmission; it has since 
been temporarily revised to implement hospital-based 
isolation of suspected cases in a specific ward. Hospi-
talization of suspected cases became necessary due to 
the length of time required to receive laboratory results 
(average: 4.1 days) and the need to control the risk of 
potential transmission during this time.

We describe the implementation of the initial 
COVID-19 surveillance system established in Vanuatu 
between January and April 2020, focusing on its de-
sign, challenges and the modifications required.

Ethics statement

The Vanuatu Health Research Ethics Committee ad-
vised that ethics approval was not required because 
data were being collected as part of the pandemic 
response and in line with the Vanuatu Public Health 
Act No. 22 of 1994.

THE SURVEILLANCE SYSTEM, MODIFI-
CATIONS AND INTERVENTIONS

The objective of the COVID-19 surveillance system in 
Vanuatu is to rapidly identify and contain any imported 
or community-acquired cases of COVID-19 (Table 1). 
The framework for surveillance systems suggested by 
Heymann4 was used to describe the system, which col-
lates data from several sources.

Existing data collection systems

The Vanuatu Public Health Sentinel Surveillance 
Network is part of the regional Pacific Public Health 
Surveillance Network.5 Eleven sites in Vanuatu report 
weekly on five core syndromes: (i) acute fever and rash, 
(ii) prolonged fever, (iii) influenza-like illness (ILI), (iv) 
watery diarrhoea, and (v) illnesses that are like dengue, 
Zika or Chikungunya.5 These syndromes are monitored 
as part of the all-hazards approach to tracking infectious 
diseases related to both outbreaks and natural disasters. 
Data are compiled weekly and sent to the national sur-
veillance unit via e-mail, phone or short message service 
(that is, SMS or text), and they are manually entered 
into a custom Excel database. ILI data are monitored 
because the symptoms of COVID-19 are clinically similar 
to influenza (Table 2). A pre-established threshold was 
set (N = 426 per week) to generate an alert and prompt 
action if the number of reported cases is greater than 
expected for seasonal influenza. Standard reporting is 
by epidemiological week (epi week), with week 1 ending 
5 January 2020.  



WPSAR Vol 12, No 2, 2021  | doi: 10.5365/wpsar.2020.11.2.012https://ojs.wpro.who.int/ 3

COVID-19 surveillance in Vanuatu, January–April 2020Williams et al

Table 1. Main objectives and interventions of the surveillance response to the COVID-19 pandemic, as per the 
VanGov Plan (COVID-19 Health Sector Preparedness and Response Plan), Vanuatu, January–April 2020

COVID-19: coronavirus disease 2019; ILI: influenza-like illness; SARI: severe acute respiratory infection.

Objectives

Scenario and interventions

1 (no cases)
2 (≥ 1 case, imported or 

locally detected [sporadic], 
OR clusters of cases)

3 (community 
transmission)

Early detection and 
isolation of suspected 
COVID-19 cases by an 
active and functional 
surveillance system

Use WHO definition to test 
suspected cases. 

Train workers at sentinel 
sites, health-care workers 
and private practitioners 
about case definition and 
notification and reporting 
channels.

Use WHO definition to test 
suspected cases. 

Provide refresher training 
to workers at sentinel sites, 
health-care workers and 
private practitioners about case 
definition and notification and 
reporting channels.

Enhance syndromic 
surveillance system, focusing 
on influenza-like illness and 
COVID-19 in public health 
facilities, and enhance event-
based surveillance system in 
private health facilities.

Test if patient has symptoms, 
and implement contact tracing 
and monitoring.

Enhance syndromic 
surveillance system,  
focusing on influenza-like 
illness and COVID-19 in 
public health facilities, 
and enhance event-based 
surveillance system in 
private health facilities.

Implement sampling strategy 
for testing, depending on 
number of suspected cases.

Table 2. Summary of sentinel and hospital surveillance activities related to the COVID-19 pandemic, Vanuatu, 
January–April 2020

 Network or site Number of sites
Coverage 

area Site type (number) Start date
Type of data used 

for COVID-19 
surveillance

Vanuatu Public 
Health Sentinel 
Surveillance 
Network

11 National Hospital (n = 6)
Health centre (n = 5)

Predated 
COVID-19

ILI

General practitioner 
sentinel sites

7 Port Vila only Private clinic (n = 5) 23 March 2020 ILI

Hospital-based 
surveillance

6 National Hospital (n = 6) 20 March 2020 ILI (captured through 
the Vanuatu Public 
Health Sentinel 
Surveillance Network),  
SARI, pneumonia, 
deaths, 
number of 
paracetamol tablets 
dispensed

COVID-19: coronavirus disease 2019; WHO: World Health Organization.



WPSAR Vol 12, No 2, 2021  | doi: 10.5365/wpsar.2020.11.2.012 https://ojs.wpro.who.int/4

Williams et alCOVID-19 surveillance in Vanuatu, January–April 2020

IMPLEMENTATION OF THE NEW SYSTEM 
JANUARY–APRIL 2020

Existing systems

The number of ILI cases reported through the Vanuatu 
Public Health Sentinel Surveillance Network fluctuated 
between epi week 1 (EW1) and EW18 (range: 156–489; 
Table 3). In EW18, there were 212 reports of ILI, a 
decrease of 25 from the previous week (n = 237). The 
number of ILI reports did not reach the threshold during 
the period (Table 3).

Enhancement for COVID-19 surveillance

Among reports submitted from seven private clinics in 
the general practitioners’ sentinel surveillance system 
between EW14 and EW18, there were also fluctuations 
in the number of consultations for ILI (range: 6–45), and 
a sustained increase was not observed (Table 3).

Only pneumonia-related hospitalization data were 
available for the period; SARI data were not available. 
Pneumonia hospitalization data were received from five of 
six hospitals in Vanuatu beginning in EW14. The number 
of new admissions for pneumonia decreased from four to 
one between EW14 and EW18 (Table 3). The number 
of paracetamol tablets dispensed through the emergency 
department was greatest in EW17 (n = 1340, Table 3).

Enhancing case investigation and management

Between January and April 2020, two people met the 
WHO case definition of a suspected case. Both patients 
had symptoms of ILI and had recently travelled overseas. 
Both of these patients isolated at home until the results 
of their COVID-19 tests were known. These patients were 
reported as suspected cases on 19 March and 30 March 
2020.

Laboratory testing of specimens

Between January and April 2020, COVID-19 testing was 
not available in Vanuatu, and all specimens were sent 
to New Caledonia for molecular testing. As of 30 April 
2020, 24 specimens from 19 people had been sent to 
New Caledonia; of these, specimens were from eight 
people identified in private clinics (42%), two people from 
government-run health clinics (11%) and the remainder 

Laboratory testing

Vanuatu’s strategy for COVID-19 laboratory testing during 
the period of interest was to collect and refer for testing 
specimens from individuals who met WHO’s definition 
of a suspected case.6 In limited circumstances and in 
consideration of the global shortage of molecular test-
ing reagents for COVID-19,7 precautionary testing was 
undertaken for selected additional individuals.

Isolation and treatment of cases

Since February 2020, the Vanuatu health ministry has 
undertaken significant measures to strengthen the coun-
try’s medical capacity to manage patients with severe 
COVID-19, including establishing a dedicated intensive 
care unit for patients needing critical care and a ward for 
patients with mild disease who cannot isolate at home.

Contact management, identification, case find-
ing and quarantine

Protocols using WHO’s definition of a close contact6 were 
established for contact tracing  to rapidly identify contacts 
of confirmed cases to determine possible sources of in-
fection and to prevent onward transmission. The protocol 
specified that asymptomatic close contacts of confirmed 
cases were to be quarantined in a designated facility or 
at home for 14 days from their last date of exposure, as 
per Section 12 of the Vanuatu Public Health Act No. 22 
of 1994, which allows for the isolation and detainment 
of a person recently exposed to infection or who may 
be in the incubation stage of any notifiable disease.8 If 
close contacts developed symptoms, as per the WHO 
case definition,6 they were to be referred to hospital for 
isolation and testing.

Management of international arrivals

Quarantine in a government-designated facility for a peri-
od of 14 days is required for all people arriving in Vanuatu 
from 20 March 2020 onwards. Protocols were developed 
to monitor people in quarantine: provincial public health 
teams conducted daily visits to screen for symptoms of 
respiratory illness and fever. All people working in the 
quarantine facilities, including transport providers, hotel 
front desk clerks, cleaners, kitchen workers and security 
officers received training from the Vanuatu Ministry of 
Health.



WPSAR Vol 12, No 2, 2021  | doi: 10.5365/wpsar.2020.11.2.012https://ojs.wpro.who.int/ 5

COVID-19 surveillance in Vanuatu, January–April 2020Williams et al

Contact management and quarantine

As there were no confirmed cases during the study pe-
riod, contact tracing was not initiated.

Managing international arrivals

As of 30 April 2020, a total of 98 people arriving 
from overseas had completed quarantine. The majority 
(n = 61; 62%) were passengers on the two last flights ar-
riving into Vanuatu on 21 March 2020 before the border 
was closed.

DISCUSSION

The aims of a national surveillance system depend on a 
country’s pandemic response strategy as well as the local 

(n = 9; 47%) were identified through the Vila Central 
Hospital emergency department or outpatient clinic. Due 
to border control measures, each dispatch of samples 
required government approval and significant logistical 
coordination. The average number of days from specimen 
collection to test result was 4.1, with a range of 1–12 
days. The samples from the two patients who met the 
WHO definition of a suspected case had test results in 
2 and 5 days and both were identified by private clin-
ics. The remainder of cases did not meet the WHO case 
definition and so had precautionary tests. None of the 
samples tested during this period was positive.

Isolation and treatment

As there were no confirmed cases during the study period, 
the isolation and treatment of cases was not required.

NC: data not collected prior to March 2020 when additional surveillance activities were implemented.

Table 3. Data collected  through various surveillance activities for COVID-19, by epidemiological week (epi week), 
Vanuatu, January–April 2020

Week Indicator (system)

Start date End date Epi week

Influenza-
like illness 

(Vanuatu Public 
Health Sentinel 

Surveillance 
Network)

Influenza-
like illness 

(private clinic 
syndromic 

surveillance)

Pneumonia 
(hospital 

surveillance)

Number of tablets 
of paracetamol 

dispensed through 
emergency 
department

30/12/2019 5/01/2020 1 489 NC NC NC

6/01/2020 12/01/2020 2 250 NC NC NC

13/01/2020 19/01/2020 3 205 NC NC NC

20/01/2020 26/01/2020 4 341 NC NC NC

27/01/2020 2/02/2020 5 191 NC NC NC

3/02/2020 9/02/2020 6 238 NC NC NC

10/02/2020 16/02/2020 7 205 NC NC NC

17/02/2020 23/02/2020 8 171 NC NC NC

24/02/2020 1/03/2020 9 319 NC NC NC

2/03/2020 8/03/2020 10 198 NC NC NC

9/03/2020 15/03/2020 11 292 NC NC NC

16/03/2020 22/03/2020 12 273 NC NC NC

23/03/2020 29/03/2020 13 268 18 NC NC

30/03/2020 5/04/2020 14 224 45 4 50

6/04/2020 12/04/2020 15 156 40 4 170

13/04/2020 19/04/2020 16 209 14 2 915

20/04/2020 26/04/2020 17 237 6 1 1340

27/04/2020 3/05/2020 18 212 13 1 790



WPSAR Vol 12, No 2, 2021  | doi: 10.5365/wpsar.2020.11.2.012 https://ojs.wpro.who.int/6

Williams et alCOVID-19 surveillance in Vanuatu, January–April 2020

In the context of having no confirmed cases and in 
the absence of widespread availability of pharmaceuti-
cal interventions, such as treatment or vaccination, 
reopening the border may result in the importation of 
COVID-19 to Vanuatu. The various surveillance compo-
nents described here are critical to rapidly detecting and 
containing any imported cases. Mathematical modelling 
data are not available to enable Vanuatu to predict the 
impact of imported cases using current population data 
and COVID-19 parameters, but they would be useful to 
guide the evolving response.

Several PICTs were also affected by Tropical Cy-
clone Harold in April 2020.12 Harold impacted Vanuatu 
on 6–7 April 2020 as a category 5 cyclone. More than 
160 000 people, approximately 55% of the population, 
reside in areas that were affected by the cyclone.13 
Harold occurred during a period of rapid scale-up and 
strengthening of COVID-19 surveillance activities. The 
implementation and strengthening of ILI surveillance in 
provinces affected by the cyclone were complicated by 
the emergence of several post-disaster outbreak-prone 
diseases that also have symptoms of ILI, such as dengue 
and leptospirosis. Where possible, the Vanuatu health 
ministry sought to harmonize surveillance activities, as 
demonstrated through the collection of data about ILI 
and injuries through pre-existing and new surveillance 
activities. Strategies to conduct disease surveillance 
for two events simultaneously at such a large scale is 
unprecedented in Vanuatu and elsewhere, and guideline 
developers should consider providing information about 
how to respond to a similar situation in the future.

Several additional limitations should be consid-
ered when assessing the implementation of Vanuatu’s 
COVID-19 surveillance; these include pre-existing 
shortages of clinical and public health workers, limited 
pre-existing epidemiological capacity within Vanuatu’s 
health ministry, the country’s geographical isolation 
and small population, and its limited laboratory capac-
ity. Nonetheless, the Vanuatu health ministry and its 
partners have rapidly scaled up surveillance activities in 
a complex, challenging and rapidly changing epidemio-
logical landscape.

The COVID-19 response is continuing in Vanuatu 
and will adapt as the epidemiological context changes. 
Lessons from the early implementation of surveillance 

epidemiological context and laboratory and health facil-
ity capacities. The objectives may be to identify severe 
cases, asymptomatic cases, clusters of cases or a combi-
nation of these. Because no cases have been detected in 
Vanuatu as of 30 April 2020, the aims of surveillance for 
COVID-19 are to rapidly detect and contain any imported 
cases. Achieving these aims relies on timely and accurate 
laboratory testing. The absence of in-country testing 
between January and April 2020 significantly limited 
Vanuatu’s initial capacity to respond effectively to the 
COVID-19 threat.

For most PICTs, including Vanuatu, in-country 
laboratory testing was not available until May 2020. 
If a case had been detected before May, the capacity 
of the country to implement timely containment and 
mitigation measures would have been reduced due 
to the lag between specimen collection and receiving 
results. In March 2020, a rapid molecular test using the  
GeneXpert platform (Cepheid, Sunnyvale, CA, USA), 
which provides fully automated, easy-to-use point-of-
care molecular testing,9 was approved for COVID-19 
testing by the US Food and Drug Administration. The 
Joint Incident Management Team (coordinated by 
the WHO Representative Office in the South Pacific)   
procured GeneXpert cartridges and machines from the 
manufacturer for distribution across PICTs.10 As a result, 
in-country laboratory testing in Vanuatu became avail-
able in May 2020, and this has strengthened Vanuatu’s 
capacity to respond to COVID-19. A testing strategy has 
been developed that considers both the epidemiological 
situation in Vanuatu and the anticipated limited avail-
ability of cartridges due to staggered distribution and 
the global shortage of consumables, including swabs.

The absence of confirmed cases in Vanuatu and 
elsewhere cannot be interpreted as an absence of circu-
lating virus, especially in countries where there is lim-
ited testing capacity. Currently, there is no international 
guidance about how to verify the absence of circulating 
virus. Data collected by the various syndromic surveil-
lance systems in Vanuatu will continue to be used to 
monitor and verify the absence of confirmed cases. In-
ternationally, severe and critical cases comprise around 
20% of diagnosed cases of COVID-1911 and, therefore, 
we assume that any undetected circulating virus would 
result in an increase in ILI in primary health care facili-
ties and pneumonia in hospitals. 



WPSAR Vol 12, No 2, 2021  | doi: 10.5365/wpsar.2020.11.2.012https://ojs.wpro.who.int/ 7

COVID-19 surveillance in Vanuatu, January–April 2020Williams et al

Conflicts of interest

All authors declare they have no conflicts of interest.

Funding statement

The Vanuatu Ministry of Health has received funding to 
support its response to COVID-19 from several partners, 
including the Asian Development Bank, the Australian 
Department of Foreign Affairs and Trade, the New Zea-
land Ministry of Foreign Affairs and Trade, the United 
Nations Children’s Fund, the United Nations Population 
Fund, the United States Agency for International Devel-
opment and the World Health Organization.

References

1. Asia Pacific strategy for emerging diseases and public health 
emergencies (APSED III): advancing implementation of the In-
ternational Health Regulations (2005). Manila: World Health Or-
ganization Regional Office for the Western Pacific; 2017. Available 
from: https://iris.wpro.who.int/handle/10665.1/13654, accessed 
28 May 2020. 

2. Coronavirus disease 2019 (COVID-19): situation report –101, 30 
April 2020. Geneva: World Health Organization; 2020. Available 
from: https://www.who.int/emergencies/diseases/novel-coronavi-
rus-2019/situation-reports, accessed 28 May 2020.

3. VanGov Plan: COVID-19 Health Sector Preparedness and Re-
sponse Plan, 8 April 2020. Port Vila: Vanuatu Ministry of Health; 
2020. Available from: https://covid19.gov.vu/index.php/know-do/
vangov-plan, accessed 28 May 2020.

4. Heymann DL. Control of communicable diseases manual, 20th 
edition. Washington (DC): American Public Health Association; 
2015.

5. Kool JL, Paterson B, Pavlin BI, Durrheim D, Musto J, Kolbe A. 
Pacific-wide simplified syndromic surveillance for early warning of 
outbreaks. Glob Public Health. 2012;7(7):670–81. doi:10.1080/
17441692.2012.699536 pmid:22823595

6. Global surveillance for human infection with novel coronavirus 
(2019-nCoV):interim guidance, 31 January 2020. Geneva: World 
Health Organization; 2020. Available from: https://apps.who.int/
iris/handle/10665/330857, accessed 28 May 2020. 

7. Laboratory testing strategy recommendations for COVID-19: 
interim guidance, 21 March 2020. Geneva: World Health Or-
ganization;  2020. Available from: https://apps.who.int/iris/han-
dle/10665/331509, accessed 28 May 2020.

8. Public Health Act No. 22 of 1994. Port Vila, Vanuatu: Republic 
of Vanuatu; 1994. Available from: http://www.paclii.org/vu/legis/
num_act/pha1994126.pdf, accessed 28 May 2020.

9. Xpert® Xpress SARS-Cov-2: instructions for use. For use under 
an Emergency Use Authorization (EUA) only. Silver Spring (MD): 
US Food and Drug Administration; 2021. Available from: https://
www.fda.gov/media/136314/download, accessed 27 January 
2021.

activities during Scenario 1 (no cases), the changing 
landscape of laboratory testing and pharmaceutical in-
terventions, as well as the global experience, particularly 
in other PICTs, will inform the refinement of COVID-19 
surveillance activities in Vanuatu.

Acknowledgements

The Vanuatu Ministry of Health’s National Health Emer-
gency Operations Centre comprises the following organiza-
tions (and individuals): Vanuatu Ministry of Health (Agnes  
Matthias, Cassidy Vusi, Edmond Tavala, George Pakoa, 
Henry Lakeleo, Jean Jacques Rory, Jimmy Obed, Julian 
Lasekula, Karel Haal, Kenslyne Lele, Len Tarivonda, 
Leonard Tabilip, Mahlon Tari, Melissa Binihi, Menie 
Nakomaha, Meriam Ben, Nellie Ham, Nerida Hinge,  
Rebecca Iaken, Renata Amos, Charlie Robinson,  
Roderick Mera, Russel Tamata, Sam Posikai, Sam 
Mahit, Sandy Moses Sawan, Sero Kalkie, Vincent Atua, 
Viran Tovu, Wendy Williams, Wesley Donald, Wilson 
Lilip, Yvette Nale), Australian Volunteers Program  
(Danielle Clark, Melanie Wratten), IsraAID (Kristina 
Mitchell), RedR (Rowan Lulu), The  Pacific Commu-
nity (Mia Ramon), United Nations Population Fund 
(Emily Deed), United Nations Children’s Fund (Lawrence  
Nimoho, Rebecca Olul, Suren Vanchinkhuu), Vanuatu 
Health Program (Caroline van Gemert, Geoff Clark, Jack 
Obed, Nish Vivekananthan, Shirley Tokon, Tim Egerton), 
World Health Organization (Fasihah Taleo, Griffith  
Harrison, Michael Buttsworth, Myriam Abel, Philippe 
Guyant, Tessa Knox, Tsogy Bayandorj).

The authors thank the clinics in the general practitioner 
sentinel surveillance system, including Novo Medical, 
The Medical Centre, Family Care Centre, Neil Thomas 
Ministries Mini Hospital, Medical Options and the 
Vanuatu Private Hospital. The authors also thank all 
the health facilities participating in the Pacific Public 
Health Surveillance Network and hospital surveillance 
systems.

Caroline van Gemert holds an Early Career Research 
Fellowship, funded by the Australian National Health 
and Medical Research Council. The Vanuatu Health 
Program is funded by the Australian Department of 
Foreign Affairs and Trade’s Australian Aid Program.

https://iris.wpro.who.int/handle/10665.1/13654
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
https://covid19.gov.vu/index.php/know-do/vangov-plan
https://covid19.gov.vu/index.php/know-do/vangov-plan
https://doi.org/10.1080/17441692.2012.699536
https://doi.org/10.1080/17441692.2012.699536
https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22823595&dopt=Abstract
https://apps.who.int/iris/handle/10665/330857
https://apps.who.int/iris/handle/10665/330857
https://apps.who.int/iris/handle/10665/331509
https://apps.who.int/iris/handle/10665/331509
http://www.paclii.org/vu/legis/num_act/pha1994126.pdf
http://www.paclii.org/vu/legis/num_act/pha1994126.pdf
https://www.fda.gov/media/136314/download
https://www.fda.gov/media/136314/download


WPSAR Vol 12, No 2, 2021  | doi: 10.5365/wpsar.2020.11.2.012 https://ojs.wpro.who.int/8

Williams et alCOVID-19 surveillance in Vanuatu, January–April 2020

12. Tropical Cyclone Harold challenges disaster and public health 
management. Geneva: World Meteorological Organization; 2020. 
Available from: https://public.wmo.int/en/media/news/tropical-cy-
clone-harold-challenges-disaster-and-public-health-management, 
accessed 28 May 2020.

13. Situation update 02: Tropical Cyclone Harold: potentially affected 
population and sectoral needs. Port Vila: Vanuatu National Dis-
aster Management Office; 2020. Available from: https://ndmo.
gov.vu/resources/downloads/categor y/99-situation-update-
infograph?download=334:02-situation-update-affected-popu-
lation-per-aerial-assessment-report-08-april-2020, accessed 8 
May 2020. 

10. Novel coronavirus (COVID-19) Pacific preparedness & response: 
Joint External Situation Report #10, 2 April 2020. Suva: World 
Health Organization Representative Office in the South Pacific; 
2020. Available from: https://www.who.int/docs/default-source/
wpro---documents/dps/outbreaks-and-emergencies/covid-19/
covid-19-pacific-situation-report-10.pdf?sfvrsn=b1c45d82_6, 
accessed 28 May 2020. 

11. Wu Z, McGoogan JM. Characteristics of and important lessons 
from the coronavirus disease 2019 (COVID-19) outbreak in China: 
summary of a report of 72 314 cases from the Chinese Center for 
Disease Control and Prevention. JAMA. 2020;323(13):1239–42. 
doi:10.1001/jama.2020.2648 PMID:32091533

https://public.wmo.int/en/media/news/tropical-cyclone-harold-challenges-disaster-and-public-health-management
https://public.wmo.int/en/media/news/tropical-cyclone-harold-challenges-disaster-and-public-health-management
https://ndmo.gov.vu/resources/downloads/category/99-situation-update-infograph?download=334:02-situation-update-affected-population-per-aerial-assessment-report-08-april-2020,accessed
https://ndmo.gov.vu/resources/downloads/category/99-situation-update-infograph?download=334:02-situation-update-affected-population-per-aerial-assessment-report-08-april-2020,accessed
https://ndmo.gov.vu/resources/downloads/category/99-situation-update-infograph?download=334:02-situation-update-affected-population-per-aerial-assessment-report-08-april-2020,accessed
https://ndmo.gov.vu/resources/downloads/category/99-situation-update-infograph?download=334:02-situation-update-affected-population-per-aerial-assessment-report-08-april-2020,accessed
https://www.who.int/docs/default-source/wpro---documents/dps/outbreaks-and-emergencies/covid-19/covid-19-pacific-situation-report-10.pdf?sfvrsn=b1c45d82_6
https://www.who.int/docs/default-source/wpro---documents/dps/outbreaks-and-emergencies/covid-19/covid-19-pacific-situation-report-10.pdf?sfvrsn=b1c45d82_6
https://www.who.int/docs/default-source/wpro---documents/dps/outbreaks-and-emergencies/covid-19/covid-19-pacific-situation-report-10.pdf?sfvrsn=b1c45d82_6
https://doi.org/10.1001/jama.2020.2648
https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32091533&dopt=Abstract